Pharma Focus Asia

FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals' DP1038 for the Treatment of Acromegaly

Wednesday, January 31, 2018

Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics announces that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DP1038, the company's investigational new drug, octreotide acetate for intranasal administration, for the treatment of acromegaly.

Acromegaly is most often caused by a benign pituitary adenoma and is characterized by clinical features including enlargement of the hands and feet, facial changes, hypertension, diabetes mellitus and cardiomyopathy. Octreotide, a somatostatin analog that suppresses excessive growth hormone production from pituitary adenomas, is the mainstay of medical management of acromegaly.

"The FDA's decision to grant DP1038 orphan drug designation for the treatment of acromegaly is an important milestone in our program as we strive to bring patients a non-injectable alternative for the management of their disease," said Joel Martin, Ph.D., President and Chief Executive Officer. "Granting of the designation highlights the unmet medical need for a new therapy that may transform the lives of these patients."

The FDA grants orphan drug status to promote the development of novel products to treat conditions affecting fewer than 200,000 people in the United States. Orphan drug designation provides significant benefits to the sponsor, including seven years of market exclusivity following marketing approval, tax credits for clinical research costs, eligibility for Orphan Product grants and the waiver of certain administrative fees.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024